Lock the Dirty Scum Conman Traitor Rapist Drump up !
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
$SYAXF added another 25K today !
$ITRM >Iterum Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results
March 16 2023 - 07:00AM
GlobeNewswire Inc.
Alert
Print
Share On Facebook
Iterum Therapeutics plc (Nasdaq: ITRM), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today reported financial results for the fourth quarter and year ended December 31, 2022.
“We made significant progress in 2022 to move the clinical development of oral sulopenem forward leading to a potential resubmission of our new drug application (“NDA”) next year,” said Corey Fishman, Iterum’s Chief Executive Officer. “Enrollment in our REASSURE trial, which is being conducted under a Special Protocol Assessment (“SPA”) agreement with the U.S. Food and Drug Administration (“FDA”), is expected to be completed in the first half of 2024.”
Highlights and Recent Events
Enrollment in REASSURE Clinical Trial Ongoing: Iterum began enrollment in its pivotal Phase 3 clinical trial, REASSURE (REnewed ASsessment of Sulopenem in uUTI caused by Resistant Enterobacterales), for the treatment of uncomplicated urinary tract infections (“uUTI”) in adult women in October 2022. Enrollment is ongoing and expected to be completed in the first half of 2024. An interim analysis at 50% patient enrollment is expected to occur in the second half of 2023. This trial is being conducted under a SPA agreement with the FDA. The SPA agreement provides that the design and planned analysis of the trial, as set out in the protocol submitted to the FDA, adequately addresses the objectives necessary to support the potential resubmission of Iterum’s NDA for oral sulopenem.
Two New U.S. Patents Issued: The United States Patent and Trademark Office has issued Iterum two new patents: 1) US Patent No. 11,478,428, directed to the composition of the bilayer tablet of sulopenem etzadroxil and probenecid (“oral sulopenem”) and its related uses, and 2) US Patent No. 11,554,112 directed to the method of use of oral sulopenem in treating multiple diseases, including uncomplicated urinary tract infections. These U.S. patents are scheduled to expire no earlier than 2039, excluding any additional term for patent adjustments or patent term extensions. Existing patent protection for sulopenem etzadroxil is scheduled to expire in 2029, subject to potential extension. Iterum’s patent portfolio also contains pending patent applications outside the U.S., including Europe and China, submitted following receipt of the Written Opinion of the International Search Authority indicating that several claims directed to the composition of the bilayer tablet of oral sulopenem are novel and inventive.
Shareholder Lawsuit Dismissed: On January 25, 2023, the putative class action lawsuit filed against Iterum, its Chief Executive Officer and Chief Financial Officer in the United States District Court for the Northern District of Illinois on August 5, 2021, was dismissed and cannot be brought back to court (dismissed with prejudice).
Fourth Quarter and Full Year 2022 Financial Results
Cash, cash equivalents and short-term investments were $60.8 million at December 31, 2022. Based on the current operating plan, Iterum expects that its current cash, cash equivalents and short-term investments will be sufficient to fund its operations until mid-2024. As of February 28, 2023, we had approximately 12.6 million ordinary shares outstanding.
Research and development (R&D) expenses for the fourth quarter and full year 2022 were $5.8 million and $17.6 million, respectively, compared to $3.7 million and $10.7 million for the same periods in 2021. The increase for the three-month period was primarily due to an increase in costs to support our REASSURE trial, which began enrollment in October 2022, partially offset by lower non-cash amortization of an intangible asset. The increase in R&D expenses for the full year was primarily due to the REASSURE trial, including an increase in headcount to support trial activities, partially offset by a decrease in consulting fees for R&D activities in 2022. Consulting fees for the year ending December 31, 2021 primarily related to consultants used during the FDA review of our NDA for oral sulopenem.
General and administrative (G&A) expenses for the fourth quarter and full year 2022 were $2.0 million and $12.8 million, respectively, compared to $3.1 million and $13.8 million for the same periods in 2021. The decrease for the three-month period was primarily due to a decrease in share-based compensation expense. The decrease for the full year period was primarily due to lower consulting fees used to support pre-commercialization activities versus the prior year, partially offset by an increase in compensation and headcount and an increase in legal fees associated with the lawsuit filed in August 2021 and dismissed with prejudice in January
2023.
Adjustments to the fair value of derivatives for the fourth quarter and full year 2022 were $3.0 million and $5.5 million, compared to $3.6 million and ($61.0) million for the same periods in 2021. The non-cash adjustment in the fourth quarter and full year 2022 primarily related to a decrease in the value of the derivative components associated with Iterum’s 6.500% Exchangeable Senior Subordinated Notes due 2025 (the “Exchangeable Notes”) as a result of a decrease in the price of its ordinary shares and market capitalization during the period. In addition, during the fourth quarter of 2022, a change in the discount rate impacted the fair value of the Limited Recourse Royalty-Linked Subordinated Notes (the “Royalty-Linked Notes”). The non-cash adjustment in the fourth quarter of 2021 primarily related to a decrease in the value of the derivative components associated with the Exchangeable Notes as a result of a decrease in the price of its ordinary shares and market capitalization during the period. The non-cash adjustment for the full year 2021 was largely due to the fair value adjustments recorded at the time of conversion of $39.2 million of the Exchangeable Notes in 2021.
Cancellation of share options for the full year 2022 was $17.4 million and related to the non-cash charge in connection with employee share options that were surrendered and cancelled in July 2022.
Net loss for the fourth quarter and full year 2022 was $5.1 million and $44.4 million, respectively, compared to a net loss of $4.2 million and $91.6 million for the same periods in 2021. Non-GAAP1 net loss for the fourth quarter and full year 2022 of $6.4 million and $22.9 million, respectively, compared to a non-GAAP1 net loss of $3.3 million and $19.4 million for the same periods in 2021.
Conference Call Details
Iterum will host a conference call today, Thursday, March 16, 2023 at 8:30 a.m. Eastern Time. The dial-in information for the call is as follows: United States: 1 844 200 6205; International: 1 929 526 1599; Access code: 846586
About Iterum Therapeutics plc
SYAXF > VW’s first battery plant outside of Europe will be in Canada https://driving-ca.cdn.ampproject.org/c/s/driving.ca/auto-news/local-content/vw-volkswagen-first-battery-plant-outside-europe-canada-st-thomas-ontario-gigafactory/wcm/fec8ae3f-0600-4b0b-9568-6602e3b49dc0/amp/?fbclid=IwAR2wFklKV545fT2HgeBEktls1n-xtjiKHM7cIoLI1s76bMDsK5aCi70ES3o
VW’s first battery plant outside of Europe will be in Canada https://driving-ca.cdn.ampproject.org/c/s/driving.ca/auto-news/local-content/vw-volkswagen-first-battery-plant-outside-europe-canada-st-thomas-ontario-gigafactory/wcm/fec8ae3f-0600-4b0b-9568-6602e3b49dc0/amp/?fbclid=IwAR2wFklKV545fT2HgeBEktls1n-xtjiKHM7cIoLI1s76bMDsK5aCi70ES3o
AMPG liking the Trend ! up
AMPG I see $5.00 in our future again!
AMPG. Looking very good here !
SYAXF may add a few more today, Opportunity knocking on the door ! imho
AMPG TDAmertrade > Moderate buy
Based on the 1 sell side analysts who offered a 12-month price target in the last three months.
Buy (1)Hold (0)Sell (0)
Low price target$8.00
Average price target$8.00
High price target$8.00
View Expert Insights
Ford
Reiterated since 01/14/2023
1
2
3
4
5
More Positive
Neutral
More Negative
$XCRT will pass your price avg. soon enough. )))
SYAXF repost of a great article in N Y TImes !
About 350 miles northwest of Montreal, amid a vast pine forest, is a deep mining pit with walls of mottled rock. The pit has changed hands repeatedly and been mired in bankruptcy, but now it could help determine the future of electric vehicles.
The mine contains lithium, an indispensable ingredient in electric car batteries that is in short supply. If it opens on schedule early next year, it will be the second North American source of that metal, offering hope that badly needed raw materials can be extracted and refined close to Canadian, U.S. and Mexican auto factories, in line with Biden administration policies that aim to break China’s dominance of the battery supply chain.
Having more mines will also help contain the price of lithium, which has soared fivefold since mid-2021, pushing the cost of electric vehicles so high that they are out of reach for many drivers. The average new electric car in the United States costs about $66,000, just a few thousand dollars short of the median household income last year.
But the mine outside La Corne, operated by Sayona Mining, an Australian company, also illustrates the many hurdles that must be overcome to produce and process the materials needed to wean automobiles from fossil fuels. The mine has had several owners, and some of them filed for bankruptcy. As a result, some analysts and investors warn that many mines being developed now may never be viable.
Continue reading the main story
Dozens of lithium mines are in various stages of development in Canada and the United States. Canada has made it a mission to become a major source of raw materials and components for electric vehicles. But most of these projects are years away from production. Even if they are able to raise the billions of dollars needed to get going, there is no guarantee they will yield enough lithium to meet the continent’s needs.
https://www.nytimes.com/2022/09/20/business/electric-vehicles-lithium-quebec.html
$SYAXF repost of a article in N Y TImes
About 350 miles northwest of Montreal, amid a vast pine forest, is a deep mining pit with walls of mottled rock. The pit has changed hands repeatedly and been mired in bankruptcy, but now it could help determine the future of electric vehicles.
The mine contains lithium, an indispensable ingredient in electric car batteries that is in short supply. If it opens on schedule early next year, it will be the second North American source of that metal, offering hope that badly needed raw materials can be extracted and refined close to Canadian, U.S. and Mexican auto factories, in line with Biden administration policies that aim to break China’s dominance of the battery supply chain.
Having more mines will also help contain the price of lithium, which has soared fivefold since mid-2021, pushing the cost of electric vehicles so high that they are out of reach for many drivers. The average new electric car in the United States costs about $66,000, just a few thousand dollars short of the median household income last year.
But the mine outside La Corne, operated by Sayona Mining, an Australian company, also illustrates the many hurdles that must be overcome to produce and process the materials needed to wean automobiles from fossil fuels. The mine has had several owners, and some of them filed for bankruptcy. As a result, some analysts and investors warn that many mines being developed now may never be viable.
Continue reading the main story
Dozens of lithium mines are in various stages of development in Canada and the United States. Canada has made it a mission to become a major source of raw materials and components for electric vehicles. But most of these projects are years away from production. Even if they are able to raise the billions of dollars needed to get going, there is no guarantee they will yield enough lithium to meet the continent’s needs.
https://www.nytimes.com/2022/09/20/business/electric-vehicles-lithium-quebec.html
$ITRM starting the New Year off right!
$SYAXF > Sayona ranked among the ASX's top 3 #mining stocks in 2022 https://lnkd.in/gPaXQuUb $SYA $SYAXF #ASX #lithium #Quebec #EV #ESG
$XCRT nice buys today )))
"undermine Trump" you mean Lying Traitor Conman Trump ?What planet are you living on? Never forget Jan 6th & the Lying Traitor Conman
https://www.cnbc.com/2022/12/22/trump-capitol-riot-jan-6-committee-issues-final-report.html
https://www.nytimes.com/2021/01/11/us/who-died-in-capitol-building-attack.html Cop Killer POS
Happy New Year, should be a Great one!
$SYAXF Thank you added another 30K Christmas comes early! imho
XCRT make that 200K
XCRT 100k buy & GTSM doesn't move, Smells
$ITRM >Iterum Therapeutics announces Issuance of Allowance for a U.S. Patent Covering Oral Sulopenem
December 15 2022 - 08:00AM
GlobeNewswire Inc.
Alert
Print
Share On Facebook
Iterum Therapeutics plc (Nasdaq: ITRM) (the “Company” or “Iterum”), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today announced that the United States Patent and Trademark Office (“USPTO”) has issued Iterum a Notice of Allowance for U.S. patent application number 16/372,075 entitled “Combinations of Beta-Lactam Compounds and Probenecid and Uses Thereof” that covers the use of Iterum's candidate combination of sulopenem etzadroxil and probenecid in treating multiple diseases, including uncomplicated urinary tract infections.
“Following on from the patent recently issued by the USPTO directed to the composition of the bilayer tablet of sulopenem etzadroxil and probenecid (“oral sulopenem”) and its related uses, we are very pleased to strengthen our oral sulopenem patent estate further with the addition of this new patent which, when issued, will afford protection until at least 2039 and further enhance its commercial opportunity. If approved, oral sulopenem will be the first oral penem available in the United States,” said Corey Fishman, Chief Executive Officer. “Enrollment in our pivotal Phase 3 clinical trial for oral sulopenem for the treatment of uncomplicated urinary tract infections is ongoing, and we expect to provide an update following an interim analysis at 50% patient enrollment.”
This Notice of Allowance concludes the substantive examination of the patent application and will result in the issuance of a U.S. patent after administrative processes are completed. The U.S. patent scheduled to issue from this application will expire April 1, 2039, absent any extensions. The recently issued U.S. patent for oral sulopenem entitled “Combinations of Beta-Lactam Compounds and Probenecid and Uses Thereof” also expires in 2039, absent any extensions.
The Company’s patent portfolio also contains pending patent applications outside the U.S. including Europe and China, submitted following receipt of the Written Opinion of the International Search Authority indicating that several claims directed to the composition of the bilayer tablet of oral sulopenem are novel and inventive.
About Iterum Therapeutics plc
Iterum Therapeutics plc is a clinical-stage pharmaceutical company dedicated to developing differentiated anti-infectives aimed at combatting the global crisis of multi-drug resistant pathogens to significantly improve the lives of people affected by serious and life-threatening diseases around the world. Iterum Therapeutics is advancing its first compound, sulopenem, a novel penem anti-infective compound, in Phase 3 clinical development with an oral formulation and IV formulation. Sulopenem has demonstrated potent in vitro activity against a wide variety of gram-negative, gram-positive and anaerobic bacteria resistant to other antibiotics. Iterum Therapeutics has received Qualified Infectious Disease Product (QIDP) and Fast Track designations for its oral and IV formulations of sulopenem in seven indications.
$XCRT sure looks Ripe $$$
$AHAG missed the Big Buyer yesterday, Merry Christmas
$XCRT yep keep adding , your doing good!
Forbes Estimates China Paid TraitorTrump At Least $5.4 Million Since He Took Office, Via Mysterious Trump Tower Lease
https://www.forbes.com/sites/danalexander/2020/10/23/forbes-estimates-china-paid-trump-at-least-54-million-since-he-took-office-via-mysterious-trump-tower-lease/?sh=25ae2920ed11&fbclid=IwAR1ecemmE9CRRQTQ7jnPX-kGwtIzRTRXgEXz0nb64M60YrFB0n32BRUUj88
Never forget that 21 House Republicans(Who hide under Desks) voted against honoring January 6th Capitol Police with Congressional Gold Medals. 21 House Republicans voted against heroes who protected our democracy & nation’s Capitol on 1/6. Every one of them deserves to be voted out of office in 2024.
What Is QAnon, the Viral Pro-Trump(Traitor) Conspiracy Theory?
Wow on average Q followers have a I Q in the 60s
https://www.nytimes.com/article/what-is-qanon.html
Unearthed Sketch Features Donald Trump Flirting with a Drag-Dressed Rudy Giuliani in 2000
"Oh you dirty boy," Rudy Giuliani told Donald Trump
https://people.com/politics/donald-trump-motorboats-rudy-giuliani-in-drag-in-unearthed-sketch/
Trump the Conman Traitor Items with classified markings found at Trump storage unit in Florida
"The Inevitable Indictment of Donald Trump
It’s clear to me that Merrick Garland will bring charges against Donald Trump. It’s just a matter of when."
Trump's lawyers can't even believe what he tells them. There appears to be much evidence he has intentionally tried to
obstruct justice in this case. Just as it appeared he did in Mueller, III's investigation of Russia meddling in the 2016 election.
The former president’s lawyers have told federal authorities no classified material was found
in additional searches of Trump Tower in New York and his golf club in Bedminster, N.J.
By Jacqueline Alemany, Josh Dawsey, Spencer S. Hsu, Devlin Barrett and Rosalind S. Helderman
Updated December 7, 2022 at 1:05 p.m. EST|Published December 7, 2022 at 5:00 a.m. EST
Trump Tower in Manhattan in July 2020. (Biz Herman for The Washington Post)
Lawyers for Donald Trump found at least two items marked classified after an outside team hired by Trump searched a storage unit in West Palm Beach, Fla., used by the former president, according to people familiar with the matter.
Those items were immediately turned over to the FBI, according to those people, who like others spoke on the condition of anonymity to discuss sensitive matters.
The search was one of at least three searches for classified materials conducted by an outside team at Trump properties in recent weeks, after Trump’s legal team was pressed by a federal judge to attest that it had fully complied with a May grand jury subpoena to turn over all materials bearing classified markings, according to people familiar with the matter.
There has been a lengthy and fierce battle between Trump’s attorneys and the Justice Department in a Washington federal court in recent weeks, according to people familiar with the matter. Much of the legal wrangling remains under seal by a federal judge, but people familiar with the matter say the Justice Department has raised concerns about what prosecutors view as a long-standing failure to fully comply with the May subpoena by Trump’s team.
Emails released by the General Services Administration, which assists former presidents during their transition to private life, show that the government agency helped rent the storage unit at a private facility in West Palm Beach on July 21, 2021. The unit was needed to store items that had been held at an office in Northern Virginia used by Trump staffers in the months just after he left office.
VIDEO - You don’t need to be a spy to break the Espionage Act 3:52
The warrant authorizing the search of former president Donald Trump’s home said
agents were seeking documents possessed in violation of the Espionage Act.
(Video: Adriana Usero/The Washington Post)
The emails show that the GSA and Trump staffers worked together to arrange to ship several pallets of boxes and other items weighing more than 3,000 pounds from Northern Virginia to the Florida storage unit in September 2021.
A person familiar with the matter said the storage unit had a mix of boxes, gifts, suits and clothes, among other things. “It was suits and swords and wrestling belts and all sorts of things,” this person said. “To my knowledge, he has never even been to that storage unit. I don’t think anyone in Trump World could tell you what’s in that storage unit.”
There was no cataloguing of what was put in the storage unit, Trump advisers said — just as there was no cataloguing of what classified documents were taken to a room underneath Mar-a-Lago.
The Washington Post could not immediately determine specifically what was in the items marked classified. A Justice Department spokesman declined to comment. The FBI did not immediately respond to a request for comment.
The ultimate significance of the classified material in the storage unit is not immediately clear, but its presence there indicates Mar-a-Lago was not the only place where Trump kept classified material .. https://www.washingtonpost.com/politics/2022/02/10/trump-records-classified/?itid=lk_inline_manual_18 . It also provides further evidence that Trump and his team did not fully comply with a May grand jury subpoena that sought all documents marked classified still in possession of the post-presidential office.
[ Trump’s classified Mar-a-Lago documents, catalogued
https://www.washingtonpost.com/politics/2022/09/07/trump-classified-documents-fbi-search/?itid=lk_interstitial_manual_19 ]
In addition to the storage unit, the team hired an outside company to carry out the search of Trump’s golf club in Bedminster, N.J., and, more recently, Trump Tower in New York, according to people familiar with the matter. The outside team also searched at least one other property.
The team offered the FBI the opportunity to observe the search but the offer was declined, the people said. It would be unusual for federal agents to monitor a search of someone’s property conducted by anyone other than another law enforcement agency.
VIDEO - 5 things we learned from the Mar-a-Lago affidavit 1:07
National video reporter Hannah Jewell explains what we learned from the affidavit that made the case
for the FBI to search Trump's Mar-a-Lago residence. (Video: Casey Silvestri/The Washington Post)
Trump’s lawyers have told the Justice Department that the outside team did not turn up any new classified information during their search of Bedminster and Trump Tower, according to people familiar with the process, and have said they utilized a firm that had expertise in searching for documents.
The entrance to Trump National Golf Club in Bedminster, N.J., in October 2020. (Seth Wenig/AP)
“President Trump and his counsel continue to be cooperative and transparent,” Trump spokesman Steven Cheung said, accusing the Justice Department of committing an “unprecedented” and “unwarranted attack” against Trump and his family.
Chief U.S. District Judge Beryl A. Howell told Trump’s legal team to continue to search for documents after the Justice Department expressed concerns that the team had not fully complied with a subpoena earlier this year. Howell, according to people familiar with the matter, did not give specific orders on how a search should be done.
Howell’s instructions followed a breakdown in the government’s trust in Trump’s attorneys that led prosecutors in August to seek a court-authorized FBI search of Mar-a-Lago. Since that time, prosecutors have continued to question whether Trump has returned all materials with classification markings, although what steps the government might take to retrieve such materials or procedures it might require Trump’s advisers and lawyers to implement remain unclear.
Trump’s team has sought to avert another federal high-profile search of his properties, the people familiar with the matter said.
According to the people, at least one of Trump’s lawyers has previously advocated for a less combative approach toward the Justice Department investigation of Trump and his advisers for three potential crimes: mishandling of national security secrets, obstruction and destruction of government records.
That attorney, former Florida solicitor general Christopher Kise, had proposed such a search months earlier. Many of the other lawyers on Trump’s team have rebuffed Kise’s advice, and he has taken a reduced role in the classified documents case while taking a larger role in the New York investigations into the former president, the people said.
People wait for a moving van after boxes were moved out of the Eisenhower Executive Office Building,
inside the White House complex, on Jan. 14, 2021. (Gerald Herbert/AP)
Jay Bratt, the chief of the counterintelligence and export control section at the Justice Department, communicated to Trump’s lawyers after the FBI search that the department was concerned Trump still may not have returned all the classified documents in his possession. The Post has previously reported .. https://www.washingtonpost.com/politics/2022/08/27/trump-archives-records-war/?itid=lk_inline_manual_36 .. that officials at the National Archives also believe that there may still be more records missing. Previous attempts by Trump’s attorneys to identify and return documents proved unsatisfactory .. https://www.washingtonpost.com/national-security/2022/09/30/trump-lawyers-kise-corcoran-bobb/?itid=lk_inline_manual_36 .. to investigators.
At times in the past, Trump has misled his own lawyers as to what was in the boxes that were taken from Mar-a-Lago, The Post has reported.
For example, he told some on his team that he possessed only newspaper clippings and personal items in 2021. One of his former lawyers, Alex Cannon, declined Trump’s entreaty to tell the National Archives he had returned all items, because Cannon was not sure whether it was true, and his team in February did not release a statement dictated by Trump that claimed he had returned all materials, The Post has reported.
Trump lawyers Christina Bobb and Evan Corcoran met with investigators in June, handing over a taped-up folder of 38 documents collected from the former president’s residence in response to a May subpoena, according to court documents and people familiar with the matter. Prosecutors called the response “incomplete” in court documents and said that they collected evidence of “obstructive conduct” regarding the failure to fully comply with the subpoena.
Bobb signed a certification swearing that she had been told that “a diligent search” was conducted of boxes of records shipped from the White House to Florida when Trump left office and that the file handed over to investigators contained “all documents that are responsive to the subpoena.” Corcoran told the visiting investigators he had been advised that all available boxes placed in a storage room — and nowhere else — had been searched in response to the subpoena, The Post reported.
Soon after, investigators obtained video surveillance of the club .. https://www.washingtonpost.com/national-security/2022/10/13/walt-nauta-maralago-trump-documents/?itid=lk_inline_manual_45 .. and conducted more interviews with Trump staffers, leading them to seek a search warrant from a judge on the basis of new evidence that sensitive material still remained at Mar-a-Lago, The Post has reported. When agents executed the search warrant in August, they found additional documents with classified markings in the storage room and in Trump’s office, along with thousands of other government papers and items, according to court records.
Perry Stein contributed to this report.
https://www.washingtonpost.com/nation/2022/12/07/trump-tower-bedminster-records-search/
Trump’s Company Is Guilty of Tax Fraud, a Blow to the Firm and the Man(Lying, Cheating,Conman Traitor)
The Trump Organization, the family real estate business that made Donald J. Trump a billionaire and propelled him from reality television to the White House, was convicted on Tuesday of tax fraud and other crimes, forever tarring the former president and the company that bears his name.
The conviction on all 17 counts, after more than a day of jury deliberations in State Supreme Court in Manhattan, stemmed from the company’s practice of doling out off-the-books perks to executives: They received luxury apartments, leased Mercedes-Benzes, extra cash at Christmas, even free cable television. They paid taxes on none of it.
The Manhattan district attorney’s office, which prosecuted the case, had previously obtained a guilty plea from the scheme’s architect, Allen H. Weisselberg, the company’s longtime chief financial officer. Mr. Weisselberg, one of Mr. Trump’s most loyal lieutenants, testified as the prosecution’s star witness but never implicated the former president.
Prosecutors did not charge Mr. Trump, but they invoked him throughout the monthlong trial, telling jurors that he had personally paid for some of the perks and had even approved a crucial aspect of the scheme. The prosecution sounded a drumbeat of damning evidence about a freewheeling culture at his company, revealing that pervasive illegality flourished there for years.
https://www.nytimes.com/2022/12/06/nyregion/trump-org-verdict-guilty.html
$XCRT Looking very Ripe ! imho
>So we have a new nice article on XCRT distributed-
https://otcstockz.com/otc-stocks/in-the-penny-stock-market-xcelerate-inc-otc-xcrt-is-emerging-as-a-top-healthcare-service-stock-to-watch/
$XCRT Looking very Ripe ! imho
>So we have a new nice article on XCRT distributed-
https://otcstockz.com/otc-stocks/in-the-penny-stock-market-xcelerate-inc-otc-xcrt-is-emerging-as-a-top-healthcare-service-stock-to-watch/
$XCRT Here it is for those who may have missed it! Tks RJ >So we have a new nice article on XCRT distributed-
https://otcstockz.com/otc-stocks/in-the-penny-stock-market-xcelerate-inc-otc-xcrt-is-emerging-as-a-top-healthcare-service-stock-to-watch/
My takeaway from the article is if you have been here for any period of time- this article explains why you have stuck around. We’ve repeated it numerous times on this board. But this article is not for us- it’s for new eyes and its well done for people not familiar with XCRT’s accomplishments.
It lays out the positives of XCRT starting with the Management and Advisory Board Members. Every time I read it; I think about how impressive it is. To compile that many quality people on a vision without huge dilution or paying exorbitant salaries shows Mike’s management ability and contacts.
It talks about how this abandoned shell has cleaned itself up from a bankrupt dental practice to now being listed on the OTC QB. Now it is a shell risk only. That was a 2-year process and have to say took so funds to achieve but added value to XCRT
It talks about the business model that Mike has developed for the company. I view it as how the drug industry has changed over the years. The Big Boys don’t really have a R & D department anymore. They look at these smaller players developing the new drugs and don’t have the capital to bring their new drugs to market. The big boys come in and partner with them to provide the capital and the connections needed to get it approved (I won’t get on a soapbox and go into the corruption of this and how the FDA is funded by the Big Boys- that’s a whole different story).
It seems XCRT is doing this for technologies and patents but without the high costs of R & D., It is structured as an incubator to bridge the gap in the healthcare industry of new technologies and finding the right big-boy partner. It is doing it without a monthly burn rate that causes huge dilution but gives companies and technologies the ability to have a public company with incredible contacts in the industry open doors.
It seems XCRT has a 3-pronged approach to technology viable in the healthcare industry-
1. Homegrown devices- This is the drill that uses the metal alloy from Steve Gravely’s munitions patented and being adapted to the healthcare industry. With alloy nerd Dr. Anja joining the team in association with Dr. Ellegala’s surgical experience they received the medical rights to the alloy and have spent money to file new patents and develop the instruments.
This is usually an expensive process but it seems through equity in XCRT in shares the team has been willing to work for the future and belief that this product will work. To me as an investor, it makes sense that a metal that is resistant to heat and vibration would make sense in surgical instruments and having someone like Dr. Ellegala and his connections would be able to place this technology with some big players.
Why hasn’t this taken off? In my opinion, it is strictly a result of capital and the model that Mike has employed. Things take time when people are working for shares. I believe the Afiyasassa deal has used the capital they originally budgeted for the prototypes and when/if they start generating revenues from it it will be re-invested here.
Instead of diluting in a difficult capital market raise during the economy, they slowed down this project. It’s interesting that it really isn’t talked about in the article but given previous discussions and filings we that do DD know it’s still in the portfolio for future revenues.
2. Patents for healthcare products- Purchase from HS Pharma. There was over $10 million invested by HS Pharma in these patents. This is the expensive process I was talking about in the introduction. HS Pharma felt it was better to take a piece of XCRT and sell them the patents for shares then try to take the next step. Why would they do that?
a) The team at XCRT has the contacts to make this happen. Dr. Barry Marshall- a Nobel Prize winner and well-known person for taking his own medicine to prove his theories probably has great contacts for these products.
b) They needed protection in other countries and XCRT would invest the money to make that happen.
c) That’s not what they do- they do research and develop healthcare products. They finally agreed to continue to do what they do best and take a piece of equity and let another team develop the sales pipeline.
They acquired these patents in May of this year. For people to say nothing has happened with this are not paying attention-
1) In June they brought Cathy on to handle and develop the contacts for the marketing of these products-
https://www.otcmarkets.com/stock/XCRT/news/Cathy-Scangarella-to-Join-the-Advisory-Board-of-Xcelerate-Inc?id=360215
2) In August they announced filing patent applications in Korea and Europe followed by an announcement that they would market consumer products off these patents.
https://xcelerate.global/additional-countries-add-patent-protection/
Again, a perfect example of an incubator process- hire the person to run the program that has the right contacts (Cathy is in NJ which is a hotbed for consumer pharmaceutical companies) and strengthens the protection in the areas you plan to market. Also, these filings take money and time.
3. Afiyasassa- Where most of the money was spent this year from listening to Mike’s interviews. This makes sense as there is a huge need here and Dr. Ellegala has huge contacts in Tanzania. The article focuses mostly on this project as it seems to have the most promise for generating revenues in the near future.
a) Again, this is the incubation process. They are taking a proven technology in the US from an associate of Dr. Ellegala and introducing it to a place of need where Dr. Ellegala has huge connections as evidenced by 4 hospitals signing on almost immediately
.
b) This takes time and money to implement this system as everything has to be translated into Swahili and then implemented into the structure of the hospitals and the phone systems used there. It takes staff and capital to do that and where I imagine most of the monies they raised from the Reg A have been spent. This takes actual jobs and salaries to accomplish. Here is the scope of the language this is being translated into-
https://www.un.org/africarenewal/magazine/december-2021/swahili-gaining-popularity-globally#:~:text=With%20its%20origin%20in%20East,Yemen%20in%20the%20Middle%20East.
The revenue will be from the implementation of the system once the beta tests prove out. Imagine if the Ministry of Health decides to pay $1 for each user. That would make sense given the need for people to get medical care given the lack of doctors in Tanzania. Here is the quote from the article “When you consider that Tanzania has a population of close to 60.8 million people, many of whom are in urgent need of medical care, the program’s initial reach would represent a total catchment area of almost 20 million prospective patients.”
c) This would cost the Government $20 million to give healthcare to 20 million people and generate $20 million for XCRT. I think they could get a strategic partner involved for this type of opportunity not only for Tanzania but the other 13 countries that speak Swahili.
That’s my evaluation. With XCRT I just keep looking at share increases which have been a minimum IMHO and necessary for the growth of the Company (hiring Cathy and shares from Reg A is all I have seen). I don’t listen to the noise and keep an eye on progress and management. I know this is OTC land and what warning signs to look for but the structure Mike has built and executed looks sound. Yes, I’d always like to see things happen quicker but I also know that business is not easy and takes time to develop-not what investors on OTC want to hear.
As I always say- do your own DD, know what you own, and make your decisions based upon your own risk tolerance and financial planning of when you need your invested capital. I hope everyone has a wonderful, safe, and healthy holiday season.
Bullish
BULLISH
$XCRT >So we have a new nice article on XCRT distributed-
https://otcstockz.com/otc-stocks/in-the-penny-stock-market-xcelerate-inc-otc-xcrt-is-emerging-as-a-top-healthcare-service-stock-to-watch/
My takeaway from the article is if you have been here for any period of time- this article explains why you have stuck around. We’ve repeated it numerous times on this board. But this article is not for us- it’s for new eyes and its well done for people not familiar with XCRT’s accomplishments.
It lays out the positives of XCRT starting with the Management and Advisory Board Members. Every time I read it; I think about how impressive it is. To compile that many quality people on a vision without huge dilution or paying exorbitant salaries shows Mike’s management ability and contacts.
It talks about how this abandoned shell has cleaned itself up from a bankrupt dental practice to now being listed on the OTC QB. Now it is a shell risk only. That was a 2-year process and have to say took so funds to achieve but added value to XCRT
It talks about the business model that Mike has developed for the company. I view it as how the drug industry has changed over the years. The Big Boys don’t really have a R & D department anymore. They look at these smaller players developing the new drugs and don’t have the capital to bring their new drugs to market. The big boys come in and partner with them to provide the capital and the connections needed to get it approved (I won’t get on a soapbox and go into the corruption of this and how the FDA is funded by the Big Boys- that’s a whole different story).
It seems XCRT is doing this for technologies and patents but without the high costs of R & D., It is structured as an incubator to bridge the gap in the healthcare industry of new technologies and finding the right big-boy partner. It is doing it without a monthly burn rate that causes huge dilution but gives companies and technologies the ability to have a public company with incredible contacts in the industry open doors.
It seems XCRT has a 3-pronged approach to technology viable in the healthcare industry-
1. Homegrown devices- This is the drill that uses the metal alloy from Steve Gravely’s munitions patented and being adapted to the healthcare industry. With alloy nerd Dr. Anja joining the team in association with Dr. Ellegala’s surgical experience they received the medical rights to the alloy and have spent money to file new patents and develop the instruments.
This is usually an expensive process but it seems through equity in XCRT in shares the team has been willing to work for the future and belief that this product will work. To me as an investor, it makes sense that a metal that is resistant to heat and vibration would make sense in surgical instruments and having someone like Dr. Ellegala and his connections would be able to place this technology with some big players.
Why hasn’t this taken off? In my opinion, it is strictly a result of capital and the model that Mike has employed. Things take time when people are working for shares. I believe the Afiyasassa deal has used the capital they originally budgeted for the prototypes and when/if they start generating revenues from it it will be re-invested here.
Instead of diluting in a difficult capital market raise during the economy, they slowed down this project. It’s interesting that it really isn’t talked about in the article but given previous discussions and filings we that do DD know it’s still in the portfolio for future revenues.
2. Patents for healthcare products- Purchase from HS Pharma. There was over $10 million invested by HS Pharma in these patents. This is the expensive process I was talking about in the introduction. HS Pharma felt it was better to take a piece of XCRT and sell them the patents for shares then try to take the next step. Why would they do that?
a) The team at XCRT has the contacts to make this happen. Dr. Barry Marshall- a Nobel Prize winner and well-known person for taking his own medicine to prove his theories probably has great contacts for these products.
b) They needed protection in other countries and XCRT would invest the money to make that happen.
c) That’s not what they do- they do research and develop healthcare products. They finally agreed to continue to do what they do best and take a piece of equity and let another team develop the sales pipeline.
They acquired these patents in May of this year. For people to say nothing has happened with this are not paying attention-
1) In June they brought Cathy on to handle and develop the contacts for the marketing of these products-
https://www.otcmarkets.com/stock/XCRT/news/Cathy-Scangarella-to-Join-the-Advisory-Board-of-Xcelerate-Inc?id=360215
2) In August they announced filing patent applications in Korea and Europe followed by an announcement that they would market consumer products off these patents.
https://xcelerate.global/additional-countries-add-patent-protection/
Again, a perfect example of an incubator process- hire the person to run the program that has the right contacts (Cathy is in NJ which is a hotbed for consumer pharmaceutical companies) and strengthens the protection in the areas you plan to market. Also, these filings take money and time.
3. Afiyasassa- Where most of the money was spent this year from listening to Mike’s interviews. This makes sense as there is a huge need here and Dr. Ellegala has huge contacts in Tanzania. The article focuses mostly on this project as it seems to have the most promise for generating revenues in the near future.
a) Again, this is the incubation process. They are taking a proven technology in the US from an associate of Dr. Ellegala and introducing it to a place of need where Dr. Ellegala has huge connections as evidenced by 4 hospitals signing on almost immediately
.
b) This takes time and money to implement this system as everything has to be translated into Swahili and then implemented into the structure of the hospitals and the phone systems used there. It takes staff and capital to do that and where I imagine most of the monies they raised from the Reg A have been spent. This takes actual jobs and salaries to accomplish. Here is the scope of the language this is being translated into-
https://www.un.org/africarenewal/magazine/december-2021/swahili-gaining-popularity-globally#:~:text=With%20its%20origin%20in%20East,Yemen%20in%20the%20Middle%20East.
The revenue will be from the implementation of the system once the beta tests prove out. Imagine if the Ministry of Health decides to pay $1 for each user. That would make sense given the need for people to get medical care given the lack of doctors in Tanzania. Here is the quote from the article “When you consider that Tanzania has a population of close to 60.8 million people, many of whom are in urgent need of medical care, the program’s initial reach would represent a total catchment area of almost 20 million prospective patients.”
c) This would cost the Government $20 million to give healthcare to 20 million people and generate $20 million for XCRT. I think they could get a strategic partner involved for this type of opportunity not only for Tanzania but the other 13 countries that speak Swahili.
That’s my evaluation. With XCRT I just keep looking at share increases which have been a minimum IMHO and necessary for the growth of the Company (hiring Cathy and shares from Reg A is all I have seen). I don’t listen to the noise and keep an eye on progress and management. I know this is OTC land and what warning signs to look for but the structure Mike has built and executed looks sound. Yes, I’d always like to see things happen quicker but I also know that business is not easy and takes time to develop-not what investors on OTC want to hear.
As I always say- do your own DD, know what you own, and make your decisions based upon your own risk tolerance and financial planning of when you need your invested capital. I hope everyone has a wonderful, safe, and healthy holiday season.
Bullish
BULLISH
$SYAXF will be adding a few more today! glta
$XCRT good laugh watching the Sellers Buy back in !
Never forget that 21 House Republicans voted against honoring January 6th Capitol Police with Congressional Gold Medals. 21 House Republicans voted against heroes who protected our democracy & nation’s Capitol on 1/6. Every one of them deserves to be voted out of office in 2024.